Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations.
Factors associated with survival following allogeneic transplantation for myeloid neoplasms harboring TP53 mutations. Blood Adv. 2025 Mar 14.
PMID: 40085959
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines.
US Geriatric Assessment Practices for Older Adults Undergoing Hematopoietic Cell Transplantation or Chimeric Antigen Receptor T Cell Therapy: An American Society for Transplantation and Cellular Therapy Physician Survey from the Aging Special Interest Group and Committee on Practice Guidelines. Transplant Cell Ther. 2025 May; 31(5):285-296.
PMID: 39961473
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia.
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia. Bone Marrow Transplant. 2025 Feb; 60(2):135-143.
PMID: 39537780
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation.
Expedited evaluation of hereditary hematopoietic malignancies in the setting of stem cell transplantation. Haematologica. 2024 Nov 01; 109(11):3739-3744.
PMID: 38618681
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy.
Optimization of older adults by a geriatric assessment-guided multidisciplinary clinic before CAR T-cell therapy. Blood Adv. 2024 07 23; 8(14):3785-3797.
PMID: 38810262
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients.
FLT3 inhibitor maintenance after allogeneic stem cell transplantation in FLT3-mutated acute myeloid leukemia (AML) patients. Ann Transl Med. 2024 Jun 10; 12(3):49.
PMID: 38911560
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy.
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy. Leuk Lymphoma. 2024 Jun; 65(6):864-867.
PMID: 38441062
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML.
Utility or futility? A contemporary approach to allogeneic hematopoietic cell transplantation for TP53-mutated MDS/AML. Blood Adv. 2024 02 13; 8(3):553-561.
PMID: 38096805
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
PMID: 38039510